

PRESS RELEASE: 8 January 2007

Lectus Therapeutics announces preclinical 'Proof-of-Concept' data

***Data demonstrates preclinical proof of concept that
Lectus's next-generation ion-channel modulators have
potential to treat pain disorders***

Cambridge, UK 08 January 2007, Lectus Therapeutics Ltd, the drug discovery and development company focusing on next-generation ion channel modulators, announced today that the company had gained pivotal preclinical proof-of-concept data for one of its lead in-house programmes.

Lectus's Chief Executive Officer, Dr Roland Kozlowski, and Professor Stuart Bevan of King's College London presented the company's data at the 3rd Annual Pain Management Conference last month. The results described the discovery and characterisation of its novel and readily differentiated class of voltage-gated potassium (Kv) channel modulator compounds. These small molecules affect the function of ion channels via unique accessory proteins. Targeting accessory proteins has the potential to facilitate selective pharmacological control of specific ion channels and reduce side effects seen with existing, non-specific, ion channel drugs.

Data presented included Lectus's first proof-of-concept data for such compounds in preclinical pain models of inflammatory and neuropathic hyperalgesia. These data represent a significant milestone for the company and further highlight the value of the company's proprietary functional proteomics discovery platform, LEPTICS® (Leveraged Enabling Proteomics Technology for Ion Channel Screening) and its unique approach to the discovery of the next-generation of ion channel drugs.

Dr Roland Kozlowski, CEO of Lectus, commented: "Lectus is delighted to announce these important observations which represent a valuable endorsement of its approach to discovering first-in-class compounds that are clearly differentiated from existing therapeutics used in the management of neuropathic and inflammatory pain. The next stage for the company's growth will involve advancing its internal programs into development either alone or in partnership and forging discovery alliances with pharmaceutical companies."

Professor Stuart Bevan added: “I was very pleased to collaborate with Lectus and evaluate their next-generation ion-channel modulator compounds which show very good efficacy in models of hyperalgesia and may therefore have utility for the treatment of pain in humans.”

Ends

Notes to Editors

About Lectus Therapeutics and LEPTICS®

Lectus Therapeutics is an emerging UK-based drug-discovery and development company, incorporated in December 2002, specialising in the discovery and development of novel drugs for diseases associated with pain management and urinary incontinence. Lectus's vision is to become a world leader in developing next-generation ion channel therapeutics. Lectus exploits the power of its proprietary functional proteomics platform, LEPTICS® (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and builds on its knowledge of ion channels, to develop novel ion channel modulators that have the potential to offer important clinical and economic advantages over existing therapies.

Ion channels are proteins that control the flow of ions, such as sodium, calcium and potassium, into and out of mammalian cells. They are integral to muscle movement, nerve impulse transmission and cardiovascular function. Historically, drugs targeting ion channels have been very successful and still generate well in excess of \$6 billion in global sales per annum. In recent years however, efforts at identifying novel ion channel therapeutics have focussed on targeting the pore forming domains of ion channels and despite billions of dollars spent in R&D, this approach has not yielded further significant clinical success. This is believed to be mainly because of the side effects associated with the lack of specificity of this approach. Lectus' next-generation ion channel therapeutics, selectively targeting ion channel accessory proteins, are anticipated to have a significantly enhanced safety profile with resultant therapeutic and economic benefits. Lectus's preclinical 'proof-of-concept' data for its Kv channel compounds in models of hyperalgesia represent a significant milestone for the company: validation of the company's clearly differentiated mechanistic approach for pharmacological modulation of ion channels. Lectus's compounds represent a potential first-in-class therapeutic for the treatment of pain by modulating a previously unexploited ion channel target, through a novel mechanism of action.

For further information go to www.lectustherapeutics.com.

About Stuart Bevan

Professor Stuart Bevan has recently been appointed to the Scientific Advisory Board of Lectus Therapeutics. Stuart is currently Professor of Pharmacology at the Wolfson Centre for Age-Related Diseases, King's College London and brings a wealth of experience relating to mechanisms of nociception and pain management to the Company. Stuart was formerly a Director of the Novartis Institute for Medical Research.

Further information:

Lectus Therapeutics Limited

Roland Kozlowski, CEO
Tel: +44 (0)1223 496182
Fax: +44 (0)1223 496184
roland.kozlowski@lectusth.com

Northbank Communications

Gemma Bradley
Adam Michael
Tel: +44 (0) 20 7886 8150